Overview
Fahr's syndrome is characterized by bilateral, symmetrical calcification of the basal ganglia and other brain regions, often leading to neurological deficits without a clear association with other systemic diseases. 12Diagnosis
Key Diagnostic Criteria: Bilateral, symmetrical calcification in basal ganglia and other cerebral regions observed via neuroimaging (CT, MRI).
Recommended Tests:
- CT scan showing characteristic calcifications.
- MRI to differentiate from other causes of calcification and assess extent.
Additional Findings: Presence of cations such as Ca, Fe, Mg, Al, and Zn in pathologic deposits identified through advanced spectroscopic techniques. 12Management
First-Line Treatments: Currently no specific pharmacological treatment; management focuses on symptomatic relief.
Adjunctive Treatments: Addressing secondary symptoms such as seizures with anticonvulsants (e.g., valproate, levetiracetam) as needed. 12 do not provide specific drug recommendations, hence general guidance applies.Special Populations
Hypoparathyroidism: Two cases noted with concurrent hypoparathyroidism, suggesting potential association or need for calcium and vitamin D management in such patients. 2Key Recommendations
Utilize advanced imaging techniques (CT, MRI) for definitive diagnosis of Fahr's syndrome, identifying characteristic calcifications and elemental composition. (Evidence: Moderate) 12
Manage secondary symptoms such as seizures with appropriate anticonvulsants based on clinical presentation. (Evidence: Expert opinion) 12
Consider calcium and vitamin D management in patients with concurrent hypoparathyroidism. (Evidence: Weak) 2References
1 Kozik M, Kulczycki J. Laser-spectrographic analysis of the cation content in Fahr's syndrome. Archiv fur Psychiatrie und Nervenkrankheiten 1978. link
2 Duckett S, Galle P, Escourolle R, Poirier J, Hauw JJ. Presence of zinc, aluminum, magnesium in striopalledodentate (SPD) calcifications (Fahr's disease): electron probe study. Acta neuropathologica 1977. link